Nov 9, 2026 · 12 min
GLP-1 drugs sharpen pregnancy’s unanswered questions
An ‘Ozempic baby boom’? The GLP-1 pregnancy plot twist
These medications may improve fertility and pre-pregnancy health while creating contraceptive concerns and unknown risks during pregnancy.
- 1GLP-1 medications may improve ovulation and blood-sugar control for some patients before pregnancy.
- 2Tirzepatide can affect oral contraceptive absorption, making backup or non-oral contraception advisable during dose changes.
- 3Experts recommend stopping GLP-1 medications before pregnancy because fetal exposure, placental effects, nutrition, and weight rebound remain uncertain.
Don't miss
Dr. Amy Valent explains why GLP-1 medications should generally be stopped one or two months before pregnancy despite possible pre-pregnancy benefits.
The brief
Short Wave examines the “Ozempic baby boom” stories with OB-GYN Dr. Amy Valent, who helped develop professional guidance on GLP-1 drugs and pregnancy.
Valent explains that GLP-1 medications may improve ovulation and pre-pregnancy blood-sugar control, but tirzepatide can reduce oral contraceptive effectiveness by affecting absorption.
The guidance is cautious: people are generally advised to stop GLP-1 medications one or two months before pregnancy, depending on the drug’s half-life.
The central tension is that these drugs may improve health before pregnancy while raising unresolved concerns about fetal exposure, weight rebound, placental effects, and nutrition.
Valent connects the uncertainty to a broader research gap: pregnant people have long been excluded from medical studies, even as real-world medication use expands.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.